Systems biology is a method for analyzing massive amounts of multidimensional data generated by omics technologies. Cross-validation of the various technological platforms is critical

2021 ◽  
Author(s):  
Moataz Dowaidar

The value of systems biology in cardiology is becoming more recognized. There has been a tremendous rise in the number of articles in the last two decades, as publicly available datasets have been provided online and high-throughput tissue analysis has become more prevalent. In animal models, however, the future of cardiovascular medicine is less likely to be reanalyzing data and more likely to be investigating the function of GWAS-identified SNPs or network change using informatics and gene-editing technologies. These techniques, when combined with other omics interrogations and rigorous experimental design, have the potential to improve our understanding of gene-to-disease pathways.Systems biology is a method for studying large amounts of multidimensional data generated by omics technologies and, more broadly, the transition to big data in health care.Cross-validation of the various technological platforms is critical because omics studies are prone to bias and overinterpretation.Investigators must carefully determine which publicly accessible datasets, if any, to employ while conducting a systems analysis. Despite the fact that network theory and machine learning may yield amazing outcomes, these methods are not yet standardized. The studies mentioned here are excellent examples, in part because they use empirical models to support emergent systems biology results. In the few successful cases, careful experimental design, including interventional research and clinical trials, is required, in addition to the insights supplied by bioinformatics analysis of omics approaches. While it may be tempting to use emergent qualities to capture these new discoveries in more fundamental concepts, we agree with the English philosopher William of Ockham when he says, "It is futile to do with more things what can be done with fewer."

2019 ◽  
Vol 42 ◽  
Author(s):  
J. Alfredo Blakeley-Ruiz ◽  
Carlee S. McClintock ◽  
Ralph Lydic ◽  
Helen A. Baghdoyan ◽  
James J. Choo ◽  
...  

Abstract The Hooks et al. review of microbiota-gut-brain (MGB) literature provides a constructive criticism of the general approaches encompassing MGB research. This commentary extends their review by: (a) highlighting capabilities of advanced systems-biology “-omics” techniques for microbiome research and (b) recommending that combining these high-resolution techniques with intervention-based experimental design may be the path forward for future MGB research.


2010 ◽  
Vol 28 (16) ◽  
pp. 2777-2783 ◽  
Author(s):  
Ana Maria Gonzalez-Angulo ◽  
Bryan T.J. Hennessy ◽  
Gordon B. Mills

The development of cost-effective technologies able to comprehensively assess DNA, RNA, protein, and metabolites in patient tumors has fueled efforts to tailor medical care. Indeed validated molecular tests assessing tumor tissue or patient germline DNA already drive therapeutic decision making. However, many theoretical and regulatory challenges must still be overcome before fully realizing the promise of personalized molecular medicine. The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient outcomes. Systems biology integrates engineering, physics, and mathematical approaches with biologic and medical insights in an iterative process to visualize the interconnected events within a cell that determine how inputs from the environment and the network rewiring that occurs due to the genomic aberrations acquired by patient tumors determines cellular behavior and patient outcomes. A cross-disciplinary systems biology effort will be necessary to convert the information contained in multidimensional data sets into useful biomarkers that can classify patient tumors by prognosis and response to therapeutic modalities and to identify the drivers of tumor behavior that are optimal targets for therapy. An understanding of the effects of targeted therapeutics on signaling networks and homeostatic regulatory loops will be necessary to prevent inadvertent effects as well as to develop rational combinatorial therapies. Systems biology approaches identifying molecular drivers and biomarkers will lead to the implementation of smaller, shorter, cheaper, and individualized clinical trials that will increase the success rate and hasten the implementation of effective therapies into the clinical armamentarium.


2019 ◽  
Vol 411 (17) ◽  
pp. 3891-3903 ◽  
Author(s):  
Justine Ferey ◽  
Florent Marguet ◽  
Annie Laquerrière ◽  
Stéphane Marret ◽  
Isabelle Schmitz-Afonso ◽  
...  

SIMULATION ◽  
2003 ◽  
Vol 79 (12) ◽  
pp. 717-725 ◽  
Author(s):  
D. Faller ◽  
U. Klingmüller ◽  
J. Timmer

2007 ◽  
Vol 40 (4) ◽  
pp. 73-78
Author(s):  
Eva Balsa-Canto ◽  
Antonio A. Alonso ◽  
Julio R. Banga

Biofuels ◽  
2011 ◽  
Vol 2 (6) ◽  
pp. 659-675 ◽  
Author(s):  
Dominic Pinel ◽  
Pratish Gawand ◽  
Radhakrishnan Mahadevan ◽  
Vincent JJ Martin

Sign in / Sign up

Export Citation Format

Share Document